Retour
Fourchette du Jour
12,51 €
13,80 €
Fourchette 52 Semaines
5,68 €
16,74 €
Volume
1 207 980
Moyenne 50J / 200J
12,96 €
/
9,43 €
Clôture Précédente
12,74 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -3,5 | 0,4 |
| P/B | 1,9 | 2,9 |
| ROE % | -44,0 | 3,8 |
| Net Margin % | — | 3,9 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,0 | 0,2 |
Objectif de Cours des Analystes
Hold
30,43 €
+137.0%
Low: 26,00 €
High: 38,00 €
BPA Prévisionnel
-3,02 €
CA Est.
27 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
-0,92 €
-1,79 € – 0,01 €
|
280 M | 2 |
| FY2029 |
-2,97 €
-5,74 € – 0,03 €
|
70 M | 4 |
| FY2028 |
-2,52 €
-3,24 € – -1,87 €
|
52 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4 582 | 14,47 € | 66 302 € |
| Feb 24, 2026 |
AHMED NADIM
President and CEO
|
sell | 13 515 | 14,47 € | 195 562 € |
| Feb 20, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
sell | 4 398 | 13,62 € | 59 901 € |
| Feb 20, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4 982 | 13,62 € | 67 855 € |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 11 742 | 13,62 € | 165 366 € |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
other | 16 000 | 4,30 € | — |
| Feb 18, 2026 |
Savill Corrine
Chief Business Officer
|
grant | 175 000 | — | — |
| Feb 18, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
grant | 300 000 | — | — |
| Feb 18, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 206 250 | — | — |
| Feb 18, 2026 |
SUMER JACQUELYN L
Chief Legal Officer
|
grant | 230 000 | — | — |
| Feb 12, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 416 | 12,03 € | 5 004 € |
| Jan 22, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 4 000 | 12,30 € | 49 200 € |
| Dec 31, 2025 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 27 | 6,49 € | 175 € |
| Dec 23, 2025 |
AHMED NADIM
President and CEO
|
sell | 9 922 | 10,01 € | 99 319 € |
| Dec 19, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 1 345 | 10,01 € | 13 463 € |
| Dec 18, 2025 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4 632 | 9,67 € | 44 791 € |
| Dec 18, 2025 |
SUMER JACQUELYN L
Chief Legal Officer
|
sell | 3 480 | 9,67 € | 33 652 € |
| Dec 18, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2 898 | 9,67 € | 28 024 € |
| Dec 15, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 995 | 11,90 € | 11 841 € |
| Dec 12, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2 148 | 12,38 € | 26 592 € |
Points Clés
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -175,80M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-44,02%
ROIC-44,05%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,01
Current Ratio10,25
Interest Coverage0,00
Valorisation
P/E Ratio
-3,53
P/B Ratio1,90
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -219,88M |
| ROE | -44,02% | ROA | -49,04% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -175,80M |
| ROIC | -44,05% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 10,25 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -3,53 | P/B Ratio | 1,90 |
| P/S Ratio | N/A | PEG Ratio | -0,14 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 777,16M | Enterprise Value | 691,51M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 18,94M |
| Net Income | -219,88M | -167,38M | -153,16M | 111,21M | -65,57M |
| EPS (Diluted) | -3,72 | -3,11 | -3,69 | 2,38 | -1,48 |
| Gross Profit | -311 000,0 | -306 000,0 | 0,0 | 0,0 | 18,94M |
| Operating Income | -241,65M | -196,92M | -191,09M | 144,65M | -67,95M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448,37M | 621,82M | 484,18M | 561,12M | 437,19M |
| Total Liabilities | 39,64M | 31,50M | 30,29M | 26,09M | 11,81M |
| Shareholders' Equity | 408,73M | 590,33M | 453,70M | 535,03M | 424,97M |
| Total Debt | 2,68M | 2,15M | 3,59M | 5,19M | 0,0 |
| Cash & Equivalents | 88,33M | 83,01M | 98,43M | 156,15M | 59,77M |
| Current Assets | 386,76M | 414,67M | 480,19M | 474,47M | 296,56M |
| Current Liabilities | 37,74M | 30,65M | 28,14M | 22,50M | 11,75M |